DDInter849 DDInter1147
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Guselkumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Guselkumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Guselkumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Guselkumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Guselkumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Guselkumab may lead to a major life threatening interaction when taken with Upadacitinib